ArticleCurrent treatment options in gastroenterology2015
Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches.
Article in Current treatment options in gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Longitudinal Study of Fecal Microbiome and Calprotectin to Predict Response to Biological Therapy in Patients With Crohn's Disease
Reduction in Length of Hospitalization in Patients With Acute Severe Ulcerative Colitis Treated With Rescue Therapy With Infliximab by the Use of Web-app Constant-Care. One Year Follow-up, Inclusive Colectomy Rate.
A Pilot Study of Fecal Microbiota Transplant (FMT) and Its Effects in Patients With Crohn's Disease With Moderate-to-High Risk of Colonization of Adherent-Invasive E. Coli (AIEC)
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of killer-cell immunoglobulin-like receptor (KIR) genes in susceptibility to inflammatory bowel disease: systematic review and meta-analysis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Pooled it
- The Influence of Bovine Colostrum and Sodium Butyrate Supplementation on Gut Microbiota and the Intestinal-Liver Axis in Weaned Piglets.Nutrients · 2026Article
- Article
- Exploring the Impact of Cyanidin-3-Glucoside on Inflammatory Bowel Diseases: Investigating New Mechanisms for Emerging Interventions.International journal of molecular sciences · 2023Review
- Article
- Tumor cell malignancy: A complex trait built through reciprocal interactions between tumors and tissue-body system.iScience · 2022Review
- The Microbiome: the Link to Colorectal Cancer and Research Opportunities.Current treatment options in oncology · 2022Review
- Microbial and molecular differences according to the location of head and neck cancers.Cancer cell international · 2022Article
- Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets.International journal of molecular sciences · 2022Review
- Roles of Microbiota in Cancer: From Tumor Development to Treatment.Journal of oncology · 2022Review
- Protective Effects of Phoenixin-14 Peptide in the Indomethacin-Induced Duodenal Ulcer: An Experimental Study.International journal of peptide research and therapeutics · 2022Article
- Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2021Review
- Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases.Journal of clinical medicine · 2021Review
- Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches.Bosnian journal of basic medical sciences · 2021Review
- Directed Evolution of Microbial Communities.Annual review of biophysics · 2021Review
- A Novel Combination Therapy Using Rosuvastatin andPharmaceuticals (Basel, Switzerland) · 2021Article
- The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases.Microorganisms · 2021Review
- Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.International journal of molecular sciences · 2021Review
- Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease.World journal of gastroenterology · 2021Observational
- Ulcerative colitis.Nature reviews. Disease primers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
opinion statementDespite recent major strides in our understanding of the genetic and microbial influences that contribute to the development of the inflammatory bowel diseases (IBDs), their etiology continues to be enigmatic. Results from experiments in animal models of IBDs overwhelmingly support a causal role of the microbiota in these diseases, though whether such a cause-effect relationship exists in human IBDs is still uncertain. Therefore, virtually all currently approved and most often prescribed treatments for IBDs are directed toward the over-active immune response in these diseases rather than the intestinal bacteria. Nevertheless, there is an important need for non-immunosuppressive therapies that may present a more favorable risk-benefit profile such as those that selectively target the disruptions in gut microbiota that accompany IBDs. This need has led to clinical trials of various microbial-directed therapies including fecal microbial transplant, antibiotics, probiotics, and prebiotics. Unfortunately, these published studies, many of which are small, have generally failed to demonstrate a consistent benefit of these agents in IBDs, thus leading to slow acceptance of microbe-focused treatments for these conditions. In this article, we review and summarize the microbial basis for IBDs and the results of the most recent trials of fecal microbial transplant, antibiotics, probiotics, and prebiotics in IBDs. We also comment on possible safety concerns with these agents, speculate on why they have failed to show efficacy in certain clinical settings, and propose strategies to improve their usefulness.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.